Efficacy of Favipiravir Against Severe Ebola Virus Disease
Ebola Virus Disease
About this trial
This is an interventional treatment trial for Ebola Virus Disease
Eligibility Criteria
Inclusion Criteria:
- Male or famale,13 -75 years of age
- Clinical diagnosis of EVD
- Positive blood viral RNA detection
- With any one of the symptoms below:
Hemorrhage (including hematemesis, hemoptysis, hematochezia, hematuria, mucocutaneous hemorrhage), severe dehydration (including oliguria, anuria, feebleness, hypotension, tachycardia), consciousness disorders (including coma, delirium, confusion, convulsion), shock, and high blood viral load (Ct value below 20)
- Not received any therapies for EVD
- Provided written informed consent, by guardian or the patient himself
- Be able to administrate and tolerate oral administration of tablets
Exclusion Criteria:
- Severe vomiting
- Pregnancy and breast-feeding
- Received antiviral treatment against EVD
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Control
Treatment
WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
WHO-recommended therapies plus oral administration of Favipiravir